연구
-
-
연구
-
연구업적
연구업적
최근 5년 연구업적 현황
| 연도 | 2023년 | 2022년 | 2021년 | 2020년 | 2019년 | |
|---|---|---|---|---|---|---|
| SCI 논문 발표편수 |
책임 | 173편 | 163편 | 184편 | 135편 | 144편 |
| 공동 | 120편 | 115편 | 136편 | 168편 | 167편 | |
| 합계 | 293편 | 278편 | 320편 | 303편 | 311편 | |
2041. Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas.
Kim S, Koh J, Kwon D, Keam B, Go H, Kim YA, Jeon YK, Chung DH
Eur J Cancer. 2017 Apr;75:141-149. doi: 10.1016/j.ejca.2017.01.004. Epub 2017 Feb 20.
Link
2040. Prognostic implications of intratumoral CD103+ tumor-infiltrating lymphocytes in pulmonary squamous cell carcinoma.
Koh J, Kim S, Kim MY, Go H, Jeon YK, Chung DH
Oncotarget. 2017 Feb 21;8(8):13762-13769. doi: 10.18632/oncotarget.14632.
Link
2039. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D, Koh J, Kim S, Go H, Kim YA, Keam B, Kim TM, Kim DW, Jeon YK, Chung DH.
Lung Cancer. 2017 Apr;106:131-137. doi: 10.1016/j.lungcan.2017.02.008. Epub 2017 Feb 16.
Link
2038. Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy.
Cho N, Im SA, Cheon GJ, Park IA, Lee KH, Kim TY, Kim YS, Kwon BR, Lee JM, Suh HY, Suh KJ
Eur J Nucl Med Mol Imaging. 2018 Mar;45(3):328-339. doi: 10.1007/s00259-017-3849-3. Epub 2017 Nov 4.
Link
2037. Anti-tumor activity of the ATR inhibitor AZD6738 in HER2 positive breast cancer cells.
Kim HJ, Min A, Im SA, Jang H, Lee KH, Lau A, Lee M, Kim S, Yang Y, Kim J, Kim TY, Oh DY, Brown J, O`Connor MJ, Bang YJ
Int J Cancer. 2017 Jan 1;140(1):109-119
Link
2036. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park YH, Im SA, Kim SB, Sohn JH, Lee KS, Chae YS, Lee KH, Kim JH, Im YH, Kim JY, Kim TY, Lee KH, Ahn JH, Kim GM, Park IH, Lee SJ, Han HS, Kim SH, Jung KH; Korean Cancer Study Group (KCSG)
Eur J Cancer. 2017 Nov;86:385-393
Link
2035. AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells.
Min A, Im SA, Jang H, Kim S, Lee M, Kim DK, Yang Y, Kim HJ, Lee KH, Kim JW, Kim TY, Oh DY, Brown J, Lau A, O`Connor MJ, Bang YJ
Mol Cancer Ther. 2017 Apr;16(4):566-577
Link
2034. CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy.
Lee DW, Im SA, Kim YJ, Yang Y, Rhee J, Na II, Lee KH, Kim TY, Han SW, Choi IS, Oh DY, Kim JH, Kim TY, Bang YJ
Cancer Res Treat. 2017 Jul;49(3):807-815
Link
2033. Korean Cancer Patients` Awareness of Clinical Trials, Perceptions on the Benefit and Willingness to Participate.
Lim Y, Lim JM, Jeong WJ, Lee KH, Keam B, Kim TY, Kim TM, Han SW, Oh DY, Kim DW, Kim TY, Heo DS, Bang YJ, Im SA
Cancer Res Treat. 2017 Oct;49(4):1033-1043
Link
2032. Effect and Mechanisms of Diabetes Resolution According to the Range of Gastric Resection and the Length of Anastomosis in Animal Models: Implication for Gastric Cancer Surgery in Patients with Diabetes Mellitus.
Huh YJ, Son YG, Kim TH, Park JH, Oh TJ, Choi B, Min J, Cho YM, Yang HK, Lee HJ (corresponding author).
World J Surg 2017 Sep 19 [Epub ahead of print]
Link